Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel

Journal of the American Academy of Dermatology

Volumn 69, Issue 4, 2013, Pages 570-577

  Coda, Alvin B ^a   Hata, Tissa ^a   Miller, Jeremiah ^a   Audish, David ^a   Kotol, Paul ^a   Two, Aimee ^a   Shafiq, Faiza ^a   Yamasaki, Kenshi ^b   Harper, Julie C ^c   Del Rosso, James Q ^d   Gallo, Richard L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Dermatology and Skin Care Center of Birmingham   (United States)

^d Las Vegas Skin & Cancer Clinics Ltd   (United States)

Author keywords

antimicrobial peptides; azelaic acid; cathelicidin; kallikrein 5; LL 37 rosacea; serine protease

Indexed keywords

AZELAIC ACID; CATHELICIDIN; CYCLIC AMP; KALLIKREIN 5; MESSENGER RNA; SERINE PROTEINASE; TOLL LIKE RECEPTOR 2; ANTIMICROBIAL CATIONIC PEPTIDE; BIOLOGICAL MARKER; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; DICARBOXYLIC ACID; GEL; KALLIKREIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FACE ERYTHEMA; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GEL; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOTHESIS; IN VITRO STUDY; KERATINOCYTE; MAJOR CLINICAL STUDY; MALE; MOUSE; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PAPULE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PUSTULE; REAL TIME POLYMERASE CHAIN REACTION; ROSACEA; SKIN STIMULATION; STRATUM CORNEUM; THERAPY EFFECT; ANIMAL; BAGG ALBINO MOUSE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; REFERENCE VALUE; RISK FACTOR; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CELLS, CULTURED; COHORT STUDIES; DICARBOXYLIC ACIDS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GELS; HUMANS; KALLIKREINS; KERATINOCYTES; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK FACTORS; ROSACEA; SERINE PROTEASES; TREATMENT OUTCOME;

EID: 84884353255     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.05.019     Document Type: Article

References (25)

1. M.T. Pelle, G.H. Crawford, and W.D. James Rosacea, II: therapy J Am Acad Dermatol 51 2004 499 512 quiz 3-4
2. J.Q. Del Rosso, H. Baldwin, and G. Webster American Acne and Rosacea Society rosacea medical management guidelines J Drugs Dermatol 7 2008 531 533
3. R. Odom, M. Dahl, J. Dover, Z. Draelos, L. Drake, and M. Macsai Standard management options for rosacea, part 2: options according to subtype Cutis 84 2009 97 104
4. C. Kennedy Carney, W. Cantrell, and B.E. Elewski Rosacea: a review of current topical, systemic and light-based therapies G Ital Dermatol Venereol 144 2009 673 688
5. K. Yamasaki, and R.L. Gallo The molecular pathology of rosacea J Dermatol Sci 55 2009 77 81
6. J.W. Larrick, M. Hirata, J. Zhong, and S.C. Wright Anti-microbial activity of human CAP18 peptides Immunotechnology 1 1995 65 72
7. R. Koczulla, G. von Degenfeld, C. Kupatt, F. Krotz, S. Zahler, and T. Gloe An angiogenic role for the human peptide antibiotic LL-37/hCAP-18 J Clin Invest 111 2003 1665 1672
8. R.A. Dorschner, V.K. Pestonjamasp, S. Tamakuwala, T. Ohtake, J. Rudisill, and V. Nizet Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A streptococcus J Invest Dermatol 117 2001 91 97
9. K. Yamasaki, A. Di Nardo, A. Bardan, M. Murakami, T. Ohtake, and A. Coda Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea Nat Med 13 2007 975 980
10. K. Yamasaki, K. Kanada, D.T. Macleod, A.W. Borkowski, S. Morizane, and T. Nakatsuji TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes J Invest Dermatol 131 2011 688 697
11. E.J. van Zuuren, S.F. Kramer, B.R. Carter, M.A. Graber, and Z. Fedorowicz Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review Br J Dermatol 165 2011 760 781
12. H. Gollnick, and A. Layton Azelaic acid 15% gel in the treatment of rosacea Expert Opin Pharmacother 9 2008 2699 2706
13. O. Bakar, Z. Demircay, M. Yuksel, G. Haklar, and Y. Sanisoglu The effect of azithromycin on reactive oxygen species in rosacea Clin Exp Dermatol 32 2007 197 200
14. D. Thiboutot, R. Thieroff-Ekerdt, and K. Graupe Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies J Am Acad Dermatol 48 2003 836 845
15. NIST/SEMATECH e-Handbook of statistical methods. Available at: http://www.itl.nist.gov/div898/handbook/. Accessed April 2012.
16. K.N. Kanada, T. Nakatsuji, and R.L. Gallo Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin J Invest Dermatol 132 2012 1435 1442
17. K. Yamasaki, and R.L. Gallo Rosacea as a disease of cathelicidins and skin innate immunity J Investig Dermatol Symp Proc 15 2011 12 15
18. J. Schauber, R.A. Dorschner, A.B. Coda, A.S. Buchau, P.T. Liu, and D. Kiken Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism J Clin Invest 117 2007 803 811
19. T.R. Hata, and R.L. Gallo Antimicrobial peptides, skin infections, and atopic dermatitis Semin Cutan Med Surg 27 2008 144 150
20. O.E. Sorensen, D.R. Thapa, K.M. Roupe, E.V. Valore, U. Sjobring, and A.A. Roberts Injury-induced innate immune response in human skin mediated by transactivation of the epidermal growth factor receptor J Clin Invest 116 2006 1878 1885
21. J. Schauber, and R.L. Gallo Antimicrobial peptides and the skin immune defense system J Allergy Clin Immunol 124 2009 R13 R18
22. M. Frohm, B. Agerberth, G. Ahangari, M. Stahle-Backdahl, S. Liden, and H. Wigzell The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders J Biol Chem 272 1997 15258 15263
23. J. Schauber, R.A. Dorschner, K. Yamasaki, B. Brouha, and R.L. Gallo Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli Immunology 118 2006 509 519
24. C.Y. Wang, and H.I. Maibach Why minimally invasive skin sampling techniques? A bright scientific future Cutan Ocul Toxicol 30 2011 1 6
25. O.E. Sorensen, P. Follin, A.H. Johnsen, J. Calafat, G.S. Tjabringa, and P.S. Hiemstra Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3 Blood 97 2001 3951 3959